Safety and efficacy of donor-derived chimeric antigen receptor T-cell therapy in patients with relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation
10.3760/cma.j.cn121090-20230815-00068
- VernacularTitle:供者来源CAR-T细胞治疗异基因造血干细胞移植后复发急性B淋巴细胞白血病的疗效及安全性
- Author:
Yaqi ZHUO
1
;
Sanfang TU
;
Xuan ZHOU
;
Jilong YANG
;
Lijuan ZHOU
;
Rui HUANG
;
Yuxian HUANG
;
Meifang LI
;
Bo JIN
;
Bo WANG
;
Shiqi LI
;
Zhongtao YUAN
;
Lihua ZHANG
;
Lin LIU
;
Sanbin WANG
;
Yuhua LI
Author Information
1. 南方医科大学珠江医院血液科，广州 510280
- Keywords:
Donor-derived;
Chimeric antigen receptor;
Allogeneic hematopoietic stem cell transplantation;
B-cell acute lymphoblastic leukemia;
Relapsed
- From:
Chinese Journal of Hematology
2024;45(1):74-81
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigated the safety and efficacy of donor-derived CD19+ or sequential CD19+ CD22+ chimeric antigen receptor T-cell (CAR-T) therapy in patients with B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).Methods:The data of 22 patients with B-ALL who relapsed after allo-HSCT and who underwent donor-derived CAR-T therapy at the Zhujiang Hospital of Southern Medical University and the 920th Hospital of Joint Logistics Support Force of the People’s Liberation Army of China from September 2015 to December 2022 were retrospectively analyzed. The primary endpoint was overall survival (OS), and the secondary endpoints were event-free survival (EFS), complete remission (CR) rate, and Grade 3-4 adverse events.Results:A total of 81.82% ( n=18) of the 22 patients achieved minimal residual disease-negative CR after CAR-T infusion. The median follow-up time was 1037 (95% CI 546–1509) days, and the median OS and EFS were 287 (95% CI 132-441) days and 212 (95% CI 120-303) days, respectively. The 6-month OS and EFS rates were 67.90% (95% CI 48.30%-84.50%) and 58.70% (95% CI 37.92%-79.48%), respectively, and the 1-year OS and EFS rates were 41.10% (95% CI 19.15%-63.05%) and 34.30% (95% CI 13.92%-54.68%), respectively. Grade 1-2 cytokine release syndrome occurred in 36.36% ( n=8) of the patients, and grade 3-4 occurred in 13.64% of the patients ( n=3). Grade 2 and 4 graft-versus-host disease occurred in two patients. Conclusion:Donor-derived CAR-T therapy is safe and effective in patients with relapsed B-ALL after allo-HSCT.
